Business Description
CSL Ltd
ISIN : US12637N2045
Share Class Description:
FRA:CSJA: ADRTotal Employee Number:
29,904Compare
Compare
Traded in other countries / regions
CSL.AustraliaCSLLY.USACSJ.GermanyCSL N.Mexico IPO Date
2014-09-22Description
CSL is one of the largest global biotech companies and has three main segments. CSL Behring either uses plasma-derived proteins or recombinants to treat conditions including immunodeficiencies, bleeding disorders, and neurological indications. CSL Seqirus is the world's second-largest influenza vaccination business and was acquired in fiscal 2016. CSL Vifor is an iron deficiency and nephrology business and was acquired in fiscal 2023. CSL has a strong R&D track record, and the product portfolio and pipeline include nonplasma products as the firm continues to broaden its scope. Originally formed in Australia as a government-owned entity, CSL now earns roughly half its revenue in North America and a quarter in Europe.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.1 | |||||
Equity-to-Asset | 0.49 | |||||
Debt-to-Equity | 0.6 | |||||
Debt-to-EBITDA | 10.49 | |||||
Interest Coverage | 10.07 | |||||
Piotroski F-Score | 8/9 | |||||
Altman Z-Score | 2.78 | |||||
Beneish M-Score | -2.46 | |||||
WACC vs ROIC | ||||||
Growth Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 15.3 | |||||
3-Year EBITDA Growth Rate | 15.6 | |||||
3-Year EPS without NRI Growth Rate | 11.5 | |||||
3-Year FCF Growth Rate | 24.3 | |||||
3-Year Book Growth Rate | 12.5 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 1.62 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 64.15 | |||||
9-Day RSI | 62.97 | |||||
14-Day RSI | 57.26 | |||||
3-1 Month Momentum % | -30.5 | |||||
6-1 Month Momentum % | -42.56 | |||||
12-1 Month Momentum % | -57.88 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 2.57 | |||||
Quick Ratio | 1.15 | |||||
Cash Ratio | 0.25 | |||||
Days Inventory | 621.03 | |||||
Days Sales Outstanding | 142.78 | |||||
Days Payable | 188.43 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Dividend Yield % | 3.88 | |||||
Dividend Payout Ratio | 0.45 | |||||
3-Year Dividend Growth Rate | 11.6 | |||||
Forward Dividend Yield % | 3.88 | |||||
5-Year Yield-on-Cost % | 6.19 | |||||
3-Year Average Share Buyback Ratio | -0.2 | |||||
Shareholder Yield % | 4.72 |
Profitability Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 52.18 | |||||
Operating Margin % | 23.53 | |||||
Net Margin % | 4.96 | |||||
EBITDA Margin % | 13.12 | |||||
FCF Margin % | 7.98 | |||||
OCF Margin % | 16.09 | |||||
ROE % | 2.09 | |||||
ROA % | 1.03 | |||||
ROIC % | 4.21 | |||||
3-Year ROIIC % | 4.1 | |||||
ROC (Joel Greenblatt) % | 3.63 | |||||
ROCE % | 1.66 | |||||
Years of Profitability over Past 10-Year | 10 | |||||
Moat Score | 8 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 93.09 | |||||
Forward PE Ratio | 11.51 | |||||
PE Ratio without NRI | 21.24 | |||||
Shiller PE Ratio | 15.81 | |||||
Price-to-Owner-Earnings | 11.39 | |||||
PEG Ratio | 1.97 | |||||
PS Ratio | 4.61 | |||||
PB Ratio | 1.97 | |||||
Price-to-Tangible-Book | 10.32 | |||||
Price-to-Free-Cash-Flow | 57.78 | |||||
Price-to-Operating-Cash-Flow | 28.67 | |||||
EV-to-EBIT | 84.33 | |||||
EV-to-Forward-EBIT | 12.89 | |||||
EV-to-EBITDA | 45.18 | |||||
EV-to-Forward-EBITDA | 22.19 | |||||
EV-to-Revenue | 5.93 | |||||
EV-to-Forward-Revenue | 3.67 | |||||
EV-to-FCF | 74.28 | |||||
Price-to-GF-Value | 0.41 | |||||
Price-to-Projected-FCF | 1.07 | |||||
Price-to-DCF (Earnings Based) | 1.33 | |||||
Price-to-DCF (FCF Based) | 2.66 | |||||
Price-to-Median-PS-Value | 0.28 | |||||
Price-to-Peter-Lynch-Fair-Value | 1.12 | |||||
Price-to-Graham-Number | 3.13 | |||||
Earnings Yield (Greenblatt) % | 1.19 | |||||
FCF Yield % | 1.77 | |||||
Forward Rate of Return (Yacktman) % | 14.98 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return %
Total Annual Return %
CSL Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 6,910.568 | ||
| EPS (TTM) (€) | 0.175 | ||
| Beta | 0.5656 | ||
| 3-Year Sharpe Ratio | -1.25 | ||
| 3-Year Sortino Ratio | -1.38 | ||
| Volatility % | 40.42 | ||
| 14-Day RSI | 57.26 | ||
| 14-Day ATR (€) | 0.404972 | ||
| 20-Day SMA (€) | 14.73 | ||
| 12-1 Month Momentum % | -57.88 | ||
| 52-Week Range (€) | 12.7 - 43.4 | ||
| Shares Outstanding (Mil) | 1,915.65 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 8 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
CSL Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
CSL Ltd Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| General meeting for 2026 | 2026-10-27 | In 120 days | ||
| Annual report for 2026 | 2026-08-18 | In 50 days | ||
| Fourth quarter earnings conference call for 2026 | 2026-08-18 | In 50 days | ||
| Fourth quarter earnings results for 2026 | 2026-08-18 | In 50 days | ||
| USD 0.319217 Cash Dividend | 2026-03-11 | 20.40 (+0.00%) | ||
| 2:1 Stock Split | 2026-03-02 | 21.60 (+0.00%) | ||
| Second quarter earnings conference call for 2026 | 2026-02-11 10:00 | 25.25 (+0.00%) | ||
| Second quarter earnings results for 2026 | 2026-02-11 | 25.25 (+0.00%) | ||
| General meeting for 2025 | 2025-10-28 10:00 | 29.50 (+0.85%) | ||
| USD 0.405000 Cash Dividend | 2025-09-10 | 28.50 (+0.00%) |
Show
Entries
CSL Ltd Frequently Asked Questions
What is CSL Ltd(FRA:CSJA)'s stock price today?
The current price of FRA:CSJA is €16.00. The 52 week high of FRA:CSJA is €43.40 and 52 week low is €12.70.
When is next earnings date of CSL Ltd(FRA:CSJA)?
The next earnings date of CSL Ltd(FRA:CSJA) is 2026-08-18.
Does CSL Ltd(FRA:CSJA) pay dividends? If so, how much?
The Dividend Yield % of CSL Ltd(FRA:CSJA) is 3.88% (As of Today), Highest Dividend Payout Ratio of CSL Ltd(FRA:CSJA) was 0.51. The lowest was 0.39. And the median was 0.45. The Forward Dividend Yield % of CSL Ltd(FRA:CSJA) is 3.88%. For more information regarding to dividend, please check our Dividend Page.
Press Release
Articles on CSL Ltd
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers